

Resource Summary Report

Generated by [NIF](#) on Jul 28, 2026

SMARCB1/BAF47 (D8M1X) Rabbit mAb

RRID:AB_2800172

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 91735, RRID:AB_2800172

Antibody Information

URL: http://antibodyregistry.org/AB_2800172

Proper Citation: Cell Signaling Technology Cat# 91735, RRID:AB_2800172

Target Antigen: SMARCB1

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP, IHC-P, ChIP, ChIP-seq

Antibody Name: SMARCB1/BAF47 (D8M1X) Rabbit mAb

Description: This monoclonal targets SMARCB1

Target Organism: h, m, r, mk

Clone ID: Clone D8M1X

Antibody ID: AB_2800172

Vendor: Cell Signaling Technology

Catalog Number: 91735

Record Creation Time: 20250820T000543+0000

Record Last Update: 20250820T072131+0000

Ratings and Alerts

No rating or validation information has been found for SMARCB1/BAF47 (D8M1X) Rabbit mAb.

No alerts have been found for SMARCB1/BAF47 (D8M1X) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Neve B, et al. (2026) Long non-coding RNA UCA1 modulates SMARCA2-containing SWI/SNF chromatin remodeling complexes in human colorectal cancer. *iScience*, 29(1), 114283.

Zhao Z, et al. (2025) Sickle cell disease induces chromatin introversion and ferroptosis in CD8+ T cells to suppress anti-tumor immunity. *Immunity*, 58(6), 1484.

Nie H, et al. (2025) Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer. *Cancer research*, 85(18), 3471.

Sasaki M, et al. (2025) Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers. *Cancer research communications*, 5(1), 24.

Deng Q, et al. (2024) SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions. *Cancer cell*.

Duplaquet L, et al. (2024) Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer. *Cancer cell*, 42(8), 1352.

Bolomsky A, et al. (2024) IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. *Cancer cell*, 42(7), 1185.

Kotagiri S, et al. (2024) Enhancer reprogramming underlies therapeutic utility of a SMARCA2 degrader in SMARCA4 mutant cancer. *Cell chemical biology*, 31(12), 2069.

Cui L, et al. (2024) Targeting Arachidonic Acid Metabolism Enhances Immunotherapy Efficacy in ARID1A-Deficient Colorectal Cancer. *Cancer research*.

Liu W, et al. (2023) RNF138 inhibits late inflammatory gene transcription through degradation of SMARCC1 of the SWI/SNF complex. *Cell reports*, 42(2), 112097.

Zhou W, et al. (2023) Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis. *Cancer cell*, 41(4), 740.

Pintacuda G, et al. (2023) Protein interaction studies in human induced neurons indicate convergent biology underlying autism spectrum disorders. *Cell genomics*, 3(3), 100250.

Drosos Y, et al. (2022) NSD1 mediates antagonism between SWI/SNF and polycomb complexes and is required for transcriptional activation upon EZH2 inhibition. *Molecular*

cell, 82(13), 2472.

Valencia AM, et al. (2019) Recurrent SMARCB1 Mutations Reveal a Nucleosome Acidic Patch Interaction Site That Potentiates mSWI/SNF Complex Chromatin Remodeling. *Cell*, 179(6), 1342.